Evogene Ltd. (NASDAQ:EVGN) Short Interest Down 15.4% in March

Evogene Ltd. (NASDAQ:EVGN) was the target of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 28,100 shares, a drop of 15.4% from the February 28th total of 33,200 shares. Based on an average daily trading volume, of 35,800 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.5% of the company’s shares are sold short.

Evogene Trading Up 0.8 %

Shares of EVGN traded up $0.01 during midday trading on Wednesday, reaching $1.26. 3,348 shares of the company were exchanged, compared to its average volume of 89,082. Evogene has a 1-year low of $1.20 and a 1-year high of $9.00. The company has a market cap of $6.76 million, a price-to-earnings ratio of -0.28 and a beta of 1.28. The stock has a 50-day moving average price of $1.45 and a 200-day moving average price of $1.81.

Evogene (NASDAQ:EVGN) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.78. The firm had revenue of $1.61 million during the quarter, compared to analysts’ expectations of $3.63 million. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. During the same quarter in the prior year, the business earned ($1.30) EPS.

Analyst Upgrades and Downgrades

EVGN has been the subject of several research analyst reports. StockNews.com started coverage on Evogene in a research note on Wednesday, March 26th. They set a “sell” rating for the company. Alliance Global Partners reaffirmed a “buy” rating on shares of Evogene in a research report on Friday, March 7th.

Institutional Investors Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Jane Street Group LLC bought a new position in shares of Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.40% of Evogene as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.